Analysis, news, and plain-English explanations of the 2026 pharmaceutical tariff and what it means for your prescriptions.
The 13 Annex III MFN deals obligate companies to offer Americans their lowest global drug prices. Here is what MFN pricing actually means — and whether it will work.
April 12, 2026
Biosimilars are not the same as generics — but both are 0% tariff exempt. Full comparison of approval process, cost savings, and substitution rules for patients.
April 12, 2026
Insurance formulary tiers, Medicare Part D tiers, and the 6 tariff tiers in the 2026 proclamation — complete guide to understanding which tier your drug is in.
April 12, 2026
Americans pay 2–4x more for brand name drugs than patients in other developed countries. Here is why — and how the 2026 MFN tariff mechanism is trying to close the gap.
April 12, 2026
GoodRx, Cost Plus Drugs, patient assistance programs, generic switches — every tool available to reduce prescription costs in 2026, including how to navigate the tariff.
April 12, 2026
The FDA Orange Book, Purple Book, authorized generics list, and Drugs@FDA — complete guide to searching FDA drug databases for free.
April 12, 2026
NADAC is the US government benchmark for what pharmacies actually pay for drugs. How it works, why CMS publishes it, and how it connects to the 2026 tariff.
April 12, 2026
FDA Orange Book, DailyMed, NADAC, GoodRx, Cost Plus Drugs — every free drug lookup tool explained, with step-by-step instructions for finding your drug.
April 12, 2026
Average prescription drug costs by type, condition, and insurance status. Monthly costs, trends over time, and how the 2026 tariff could push prices higher.
April 12, 2026
Every drug has a brand name and a generic name. Understanding the difference can save you thousands per year — and in 2026, generics are your best protection against the tariff.
April 12, 2026
Uninsured patients and those on high-deductible plans face the most direct exposure to the 2026 pharmaceutical tariff. Here is what to watch and how to protect yourself now.
April 12, 2026
Ozempic, Wegovy, Mounjaro, and Zepbound tariff status in 2026. Novo Nordisk and Eli Lilly both signed MFN deals — here is what that means for patients.
April 12, 2026
Keytruda (Merck), Opdivo (BMS), and Avastin (Genentech) are all at 0% via MFN deals. But Pfizer and J&J oncology drugs face real risk. Full breakdown inside.
April 12, 2026
Humira biosimilars are fully exempt. Dupixent, Skyrizi, and Rinvoq pay 0% via MFN deals. Stelara and Cimzia face real risk. Everything autoimmune patients need to know.
April 12, 2026
Flat-copay patients are shielded short-term. HDHP patients are most exposed. Here is exactly how the tariff moves through the insurance system toward your wallet.
April 12, 2026
Generics, biosimilars, orphan drugs, plasma-derived therapies, cell therapies, ADCs — every category of drug that is fully exempt from the 2026 tariff, explained.
April 12, 2026
Pfizer, Johnson & Johnson, Bayer, and Takeda did not sign MFN deals. Their brand-name drugs could face the 100% default tariff. Here is what patients on these drugs need to know.
April 12, 2026
Medicare's $2,000 OOP cap protects Part D enrollees. Medicaid's rebate system absorbs most cost increases. Here is the full breakdown for government-insured patients.
April 12, 2026
NADAC is the government benchmark for what pharmacies pay for drugs. Understanding it is the key to seeing exactly how the 2026 tariff will flow through drug prices.
April 12, 2026
Generic drugs are 100% exempt from the 2026 pharmaceutical tariff. Here is exactly how to find a generic for your medication and make the switch before prices rise.
April 11, 2026
The 13 Annex III companies with 0% tariff MFN deals: who they are, which drugs are covered, and what happens to everyone else's prescriptions.
April 10, 2026
The Section 232 tariff has a massive carve-out: generics and biosimilars pay zero. With 9 out of 10 US prescriptions filled with generics, this exemption is the most important fact for most patients.
April 8, 2026
On April 2, 2026, the Trump administration signed a sweeping tariff on pharmaceutical imports. Here's what it means for the 66 million Americans who take at least one prescription drug.
April 5, 2026